BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 23846901)

  • 21. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
    J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural Killer Group 2A Expressed on Both Peripheral CD3
    Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
    J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NKG2D: A versatile player in the immune system.
    Jelenčić V; Lenartić M; Wensveen FM; Polić B
    Immunol Lett; 2017 Sep; 189():48-53. PubMed ID: 28414183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A functional polymorphism in the NKG2D gene modulates NK-cell cytotoxicity and is associated with susceptibility to Human Papilloma Virus-related cancers.
    Espinoza JL; Nguyen VH; Ichimura H; Pham TT; Nguyen CH; Pham TV; Elbadry MI; Yoshioka K; Tanaka J; Trung LQ; Takami A; Nakao S
    Sci Rep; 2016 Dec; 6():39231. PubMed ID: 27995954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of human natural killer cells during Epstein-Barr virus infection.
    Münz C
    Crit Rev Immunol; 2014; 34(6):501-7. PubMed ID: 25597312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
    Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
    J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of NKG2D haplotypes on the cell-surface expression of NKG2D protein on natural killer and CD8 T cells of peripheral blood among atomic-bomb survivors.
    Imai K; Hayashi T; Yamaoka M; Kajimura J; Yoshida K; Kusunoki Y; Nakachi K
    Hum Immunol; 2012 Jun; 73(6):686-91. PubMed ID: 22507622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
    Giuliani E; Vassena L; Cerboni C; Doria M
    Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnesium in Infectious Diseases in Older People.
    Dominguez LJ; Veronese N; Guerrero-Romero F; Barbagallo M
    Nutrients; 2021 Jan; 13(1):. PubMed ID: 33435521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses.
    Zloza A; Kohlhapp FJ; Lyons GE; Schenkel JM; Moore TV; Lacek AT; O'Sullivan JA; Varanasi V; Williams JW; Jagoda MC; Bellavance EC; Marzo AL; Thomas PG; Zafirova B; Polić B; Al-Harthi L; Sperling AI; Guevara-Patiño JA
    Nat Med; 2012 Feb; 18(3):422-8. PubMed ID: 22366950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.
    Djaoud Z; Guethlein LA; Horowitz A; Azzi T; Nemat-Gorgani N; Olive D; Nadal D; Norman PJ; Münz C; Parham P
    J Exp Med; 2017 Jun; 214(6):1827-1841. PubMed ID: 28468758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The activating receptor NKG2D of natural killer cells promotes resistance against enterovirus-mediated inflammatory cardiomyopathy.
    Klingel K; Fabritius C; Sauter M; Göldner K; Stauch D; Kandolf R; Ettischer N; Gahlen S; Schönberger T; Ebner S; Makrigiannis AP; Bélanger S; Diefenbach A; Polić B; Pratschke J; Kotsch K
    J Pathol; 2014 Oct; 234(2):164-77. PubMed ID: 24797160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
    Song H; Park H; Kim J; Park G; Kim YS; Kim SM; Kim D; Seo SK; Lee HK; Cho D; Hur D
    Immunol Lett; 2011 May; 136(2):187-93. PubMed ID: 21277902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
    Karimi M; Cao TM; Baker JA; Verneris MR; Soares L; Negrin RS
    J Immunol; 2005 Dec; 175(12):7819-28. PubMed ID: 16339517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.
    Li FY; Chaigne-Delalande B; Su H; Uzel G; Matthews H; Lenardo MJ
    Blood; 2014 Apr; 123(14):2148-52. PubMed ID: 24550228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anything that can go wrong: cytotoxic cells and their control of Epstein-Barr virus].
    Gutiérrez-Guerrero A; Espinosa-Padilla SE; Lugo-Reyes SO
    Rev Alerg Mex; 2024 Feb; 71(1):29-39. PubMed ID: 38683066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
    Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
    Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
    Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
    Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells.
    Fernández-Sánchez A; Baragaño Raneros A; Carvajal Palao R; Sanz AB; Ortiz A; Ortega F; Suárez-Álvarez B; López-Larrea C
    Epigenetics; 2013 Jan; 8(1):66-78. PubMed ID: 23235109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.